Megumi Aoki

Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 101 citations

Routine Blood Count, Cancer Immunosurveillance, Oncology +11

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 88 citations · Full text

Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients

Yumi Nonomura, Atsushi Otsuka, Chisa Nakashima et al. · OncoImmunology · 2016 · 79 citations · Full text

Interaction of Antimicrobial Peptide Magainin 2 with Gangliosides as a Target for Human Cell Binding

Yu Miyazaki, Megumi Aoki, Yoshiaki Yano et al. · Biochemistry · 2012 · 35 citations

Proteinlipid Interaction, Mg. Mg, Peptide Engineering +16

The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study

Yasuhiro Fujisawa, Taku Fujimura, Shigeto Matsushita et al. · British Journal of Dermatology · 2020 · 33 citations